Prostate specific membrane antigen (PSMA) targeting radiopharmaceuticals have been successfully used for diagnosis and therapy of prostate cancer, as illustrated by PSMA-617 (PluvictoTM). Development of optimized PSMA-targeting probes has focused on theranostic (therapy + diagnosis) approaches, where the same precursor can be radiolabeled with similar or identical nuclides, allowing for personalised dosimetry estimation and radionuclide therapy of patients. 3p-C-NETA is a promising chelator which has been shown to efficiently label therapeutic (177Lu, 161Tb, 213Bi) and diagnostic (68Ga, Al18F) nuclides1. In this study, we attached this chelator to a PSMA-targeting derivative and compared it to a derivative containing a DOTA-GA chelator and to the gold standard PSMA-617.
|Name||European Journal of Nuclear Medicine and Molecular Imaging|